Exenatide reduces doxorubicin-induced cardiac injury

被引：0

作者：

Juntao Fang ^{[1
]}

Lijuan Wang ^{[1
]}

Xiaoman Zhang ^{[1
]}

Shangyu Liu ^{[1
]}

Hui Liu ^{[1
]}

Tiewei Li ^{[1
]}

Ping Li ^{[1
]}

机构：

[1] State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital,CAMS and PUMC

来源：

中国循环杂志 | 2018年 / S1期

关键词：

Exenatide reduces doxorubicin-induced cardiac injury;

D O I：

暂无

中图分类号：

R96 [药理学];

学科分类号：

100602 ; 100706 ;

摘要：

Objective Doxorubicin (Dox) is an effective antitumor drug,which is limited due to its lethal cardiac injury in clinical application.Exenatide (Exe) is a glucagon-like peptide-1 (GLP-1) analog, it can not only regulate blood glucose, but protect the myocardium by reducing inflammation, oxidative stress and cell apoptosis. Since doxorubicininduced cardiac injury is currently thought to be mainly caused by

引用

页码：130 / 131

页数：2